The two most recent US initial public offerings by drug developers were launched by companies in the immuno-oncology field – Hutchison China MediTech Ltd. (Chi-Med) and Corvus Pharmaceuticals Inc. – showing that investors still are intrigued by cancer immunotherapies, although not at a high IPO price.
Seven drug developers have completed US IPOs so far in 2016, including four immuno-oncology firms, a gene-editing specialist, a gene...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?